Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1996-12-20
|
| pubmed:abstractText |
The aim of this study was to assess the chronic effects of a highly selective dihydropiridine calcium channel blocker, israpidine, in its sustained release form (I-SRO), on platelet functions and fibrinolytic parameters in subjects with essential hypertension (EH) combined or not with other well-known cardiovascular risk factors, such as cigarette smoking (EH+S) and type II diabetes mellitus (EH+DM). Thirty-six patients with essential hypertension with sitting diastolic blood pressures of 96-104 mmHg without (EH, n = 12) or with other risk factors (EH+S, n = 12, EH+DM, n = 12) were enrolled. After a 4-week, single-blind, placebo run-in period, the subjects received I-SRO 5 mg once daily for 18 weeks. After both placebo and 6 and 18 weeks of I-SRO treatment, the following parameters were measured: sitting blood pressure by mercury sphygmomanometer; platelet aggregation, plasma beta-thromboglobulin (BTG), platelet factor-4 (PF4), and plasminogen activator inhibitor 1 (PAI-1) by means of ELISA methods; and euglobulin lysis time before (ELT) and after standardized (10 min) venous occlusion (ELT-VO). In the group of patients as a whole compared with placebo, I-SRO significantly reduced SBP/DBP platelet aggregation, BTG, PF4, ELT, and ELT-VO. Significant reductions in these parameters were also observed in each group. In addition to the antihypertensive effect, I-SRO chronic treatment may favorably affect the platelet function and fibrinolytic system in essential hypertension with or without other cardiovascular risk factors.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Delayed-Action Preparations,
http://linkedlifedata.com/resource/pubmed/chemical/Isradipine,
http://linkedlifedata.com/resource/pubmed/chemical/Plasminogen Activator Inhibitor 1,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Aggregation Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Platelet Factor 4,
http://linkedlifedata.com/resource/pubmed/chemical/beta-Thromboglobulin
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0920-3206
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
119-23
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8842503-Antihypertensive Agents,
pubmed-meshheading:8842503-Blood Pressure,
pubmed-meshheading:8842503-Calcium Channel Blockers,
pubmed-meshheading:8842503-Delayed-Action Preparations,
pubmed-meshheading:8842503-Diabetes Mellitus, Type 2,
pubmed-meshheading:8842503-Female,
pubmed-meshheading:8842503-Fibrinolysis,
pubmed-meshheading:8842503-Humans,
pubmed-meshheading:8842503-Hypertension,
pubmed-meshheading:8842503-Isradipine,
pubmed-meshheading:8842503-Male,
pubmed-meshheading:8842503-Middle Aged,
pubmed-meshheading:8842503-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:8842503-Platelet Aggregation Inhibitors,
pubmed-meshheading:8842503-Platelet Factor 4,
pubmed-meshheading:8842503-Single-Blind Method,
pubmed-meshheading:8842503-Smoking,
pubmed-meshheading:8842503-beta-Thromboglobulin
|
| pubmed:year |
1996
|
| pubmed:articleTitle |
Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors.
|
| pubmed:affiliation |
Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial
|